A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms
Interventions: DRUG: CI-1040
Sponsor: Pfizer